Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03624816 · ClinicalTrials.gov registry record · NA
A Study to Evaluate the Safety and Efficacy of Restylane Defyne for Chin Augmentation and Correction of Chin Retrusion
A NA study, sponsored by Galderma R&D.
- Completed
- Registry status
- NA
- Development phase
- 140
- Enrollment target
NCT03624816 is a NA study that has completed, run by Galderma R&D. The registered enrollment target is 140 participants.
The verdict
NCT03624816, a NA study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- NA
- Development phase
- 140 participants
- Enrollment target
Study Summary
To demonstrate the effectiveness of Restylane Defyne for chin augmentation and correction of chin retrusion by demonstrating the superiority in responder rates relative to no treatment.
Interventions
- DEVICE Restylane Defyne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2018-08-21 |
| Est. Completion | 2020-02-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03624816
The ClinicalTrials.gov registry entry for NCT03624816 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Restylane Defyne is the first listed.
NCT03624816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03624816 about?
NCT03624816 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Restylane Defyne for Chin Augmentation and Correction of Chin Retrusion". To demonstrate the effectiveness of Restylane Defyne for chin augmentation and correction of chin retrusion by demonstrating the superiority in responder rates relative to no treatment.
What is the current status of trial NCT03624816?
This trial is currently completed. It is a NA study. The enrollment target is 140 participants. The study started on 2018-08-21. Estimated completion is 2020-02-20.
What interventions are being tested in trial NCT03624816?
The interventions under investigation include: Restylane Defyne (DEVICE).
Who is sponsoring clinical trial NCT03624816?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.